Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma
Public ClinicalTrials.gov record NCT00003535. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Antineoplastons A10 and AS2-1 in Children With High Grade Glioma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Current therapies for children with recurrent/progressive high grade gliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of children with recurrent/progressive high grade gliomas. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on children (\> 6 months of age) with recurrent/progressive high grade gliomas.
Study identification
- NCT ID
- NCT00003535
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 9 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Months to 18 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 1994
- Primary completion
- Dec 31, 1997
- Completion
- Dec 31, 1997
- Last update posted
- Mar 20, 2018
1994 – 1998
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Burzynski Clinic | Houston | Texas | 77055-6330 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated High Grade Glioma trials
Other public records listing High Grade Glioma. Sorted by last update posted; newest first. Not a recommendation.
- NCT06428045: STARLITE for Unresectable High-Grade Gliomas Recruiting
- NCT04485559: Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) Recruiting
- NCT05632562: Multiparametic Metabolic and Hypoxic PET/MRI for Disease Assessment in High Grade Glioma Recruiting
- NCT05979064: Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) Recruiting
- NCT05954858: Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma Recruiting
- NCT07416188: Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003535, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2018 · Synced Sep 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00003535 live on ClinicalTrials.gov.